Clinical Trials Logo

Spinal Cord Injuries clinical trials

View clinical trials related to Spinal Cord Injuries.

Filter by:

NCT ID: NCT04248322 Recruiting - Clinical trials for Spinal Cord Injuries

Qualitative Assessment of the Impact of TTNS on QOL and Participation

Start date: May 31, 2022
Phase:
Study type: Observational

This study through the use of semi-structured interviews or focus groups will explore the lived experience with Transcutaneous Tibial Nerve Stimulation (TTNS) with Neurogenic Lower Urinary Tract Dysfunction to generate user-defined themes regarding bladder function and catheter-related barriers and the daily impacts on one's life.

NCT ID: NCT04243161 Withdrawn - Clinical trials for Spinal Cord Injuries

RMT in Patients With Spinal Cord Injury

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Spinal Cord Injury (SCI) is an involvement of the spinal cord, a nerve cord protected by the spine and extends from the base of the brain to the lumbar region. The spinal cord lesion causes complete or incomplete paralysis of voluntary mobility and absence, partial or total, of any sensitivity below the affected area; In addition, it also involves the lack of control over the sphincters of urination and intestinal evacuation, disorders of sexuality and fertility, alterations of the Vegetative Nervous System and risk of suffering other complications not less important as: bedsores, spasticity, kidney processes, ... The cervical and dorsal cord injury severely affects respiratory function due to paralysis and deterioration of the respiratory muscles. Several types of respiratory muscle training (RMT) have been described to improve respiratory function for people with SCI in the literature. Despite the relatively small number of studies included in this review, the meta-analysis of the pooled data indicates that RMT would be effective in increasing respiratory muscle strength and also lung volumes for people with SCI. More research is needed to obtain functional results after EMR, such as dyspnea, cough efficacy, respiratory complications, hospital admissions due to respiratory complications and quality of life.

NCT ID: NCT04243044 Completed - Clinical trials for Spinal Cord Injuries

Influence of Transcutaneous Spinal Stimulation Intensity on Spasticity After SCI

Start date: April 8, 2022
Phase: N/A
Study type: Interventional

Transcutaneous spinal stimulation (TSS) is a form of electrical stimulation delivered over the skin of the spine that may be valuable for reducing spasticity without the side effects of antispasticity medications. The intensity of stimulation, or dose, that promotes the best response is not known. Understanding the response to different intensities of stimulation and how they affect spasticity will help guide rehabilitation for persons with SCI. Therefore, this study aims to identify the effects of TSS as a non-drug intervention for spasticity management.

NCT ID: NCT04241666 Recruiting - Clinical trials for Spinal Cord Injuries

Sonographic Examination of Renal Function in Individuals With Long-term Spinal Cord Injury

Start date: January 5, 2022
Phase:
Study type: Observational

Patients with long-term lower urinary tract dysfunction due to spinal cord injury presenting for a routine urodynamic control will be screened for inclusion and exclusion criteria. Suitable individuals providing written informed consent will undergo renal Doppler sonography and renal scintigraphy in addition to the routine examinations. Conclusions regarding renal function based on the clearance rate determined by scintigraphy (gold standard) will be compared with the conclusions based on Doppler sonography and Cystatin C clearance.

NCT ID: NCT04241250 Recruiting - Spinal Cord Injury Clinical Trials

Neuromodulation Techniques After SCI

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

Spinal cord injury (SCI) leads to several health-related consequences often linked to reduced levels of physical activity. Direct stimulation of the spinal cord, either through implanted devices or surface stimulation, has been combined with intense physical therapy assisted treadmill walking to facilitate independent standing and stepping. These current methods require 3-4 highly skilled therapists and may not be feasible in all rehabilitation settings, especially when considering the growing number of SCI patients each year. Therefore, the use of robotic exoskeleton suits combined with direct stimulation of the spinal cord (requiring 1-2 therapists) may offer an alternative rehabilitation approach to overcome their limited abilities to stand and walk. Such improvements may also help to reverse or eliminate other health-related consequences associated with SCI. The pilot work will provide the preliminary evidence required to design future clinical trials for Veterans and civilians with SCI to restore overground mobility.

NCT ID: NCT04241003 Completed - Clinical trials for Spinal Cord Injuries

Effects of the SmartDrive on Mobility, Activity and Shoulder Pain Among People With SCI Using Manual Wheelchairs

Start date: June 11, 2019
Phase: N/A
Study type: Interventional

This is a prospective study of manual wheelchair users with spinal cord injury (SCI). The users will be their own controls. The primary purpose of the study is to evaluate the ability of the power assist device SmartDrive to increase the ability to be mobile.

NCT ID: NCT04238013 Terminated - Clinical trials for Spinal Cord Injuries

Neuromodulation of Ankle Muscles in Persons With SCI

Start date: July 6, 2021
Phase: N/A
Study type: Interventional

The ability to voluntarily move the ankles is important for walking. After spinal cord injury (SCI), this ability is impaired because of changes in the communication between the brain, spinal cord, and body. Whole body vibration (WBV) is a treatment that increases voluntary muscle control and decreases uncontrollable muscle movement in people with SCI. The purpose of this study is to understand how WBV can impact ankle control and uncontrollable muscle movement.

NCT ID: NCT04237363 Completed - Clinical trials for Spinal Cord Injuries

Recovery of Walking in Persons With Complete Spinal Cord Injury

Start date: July 5, 2011
Phase: N/A
Study type: Interventional

We documented the impact of 1 year of underwater treadmill training and supplemental overground walk training in five adults with chronic motor-complete SCI (cSCI) who had not undergone programmed epidural spinal cord stimulation (eSCS).

NCT ID: NCT04234269 Completed - Clinical trials for Spinal Cord Injuries

Physical Activity Scale in Individuals With Spinal Cord Injury

Start date: June 1, 2019
Phase:
Study type: Observational

The aim of this study was to improve the cultural adaptation and Turkish version of the The Physical Activity Scale for Individuals With Physical Disabilities (PASIPD) and to investigate the validity and reliability of the Turkish version of PASIPD in individuals with spinal cord injury. PASIPD, which consists of 13 questions, will be adapted to Turkish by translation and back translation method. The study included 47 wheelchair-dependent patients over the age of 18 who were able to read and write Turkish (26 females, 21 males). In order to determine the reliability and internal consistency of PASIPD, item-total correlation, if item deleted cronbach alpha coefficient and cronbach alpha coefficient of the whole scale will be calculated. Test-retest method will be used for the stability of the scale. In the test-retest method, the scale will be re-applied to the same people with 7-day intervals. Pearson correlation analysis will be performed between the first test and the second test total and sub-parameters after 1 week. Test-retest reliability will be determined using the intraclass correlation coefficient (ICC). In the validity test of PASIPD; construct validity and criterion validity will be used. Test of construct validity; factor analysis and convergent and discriminant validity methods. The Barthel Index of Activities of Daily Living and Functional Independence Measure (FIM); World Health Organization Quality of Life Scale Abbreviated Version (WHOQOL-BREF), Nottingham Health Profile (NHP) and Craig Handicap Assessment and Reporting Technique (CHART-SF) will be used to convergent and discriminant validity. Manual Wheelchair Propulsion Tests will be used to demonstrate criterion validity.

NCT ID: NCT04232657 Active, not recruiting - Clinical trials for Sublesional Bone Loss Secondary to SCI

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Chronic Romo
Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

Treatment for sublesional bone loss (osteoporosis) in persons with chronic, motor-complete spinal cord injury (SCI) has been limited and unsuccessful to date. Romosozumab, a sclerostin antagonist, has potential to increase bone formation (anabolic) and decrease bone resorption (anti-catabolic) in persons with chronic SCI. Conventional anti-resorptive therapy alone would not be anticipated to reverse sublesional bone loss in a timely manner because the skeleton below the level of lesion in chronic SCI is assumed to be in a low turnover state. However, because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density (BMD). The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (>3 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur <1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab.